Conv. Plasma
Nigella Sativa
Peg.. Lambda

All acetaminophen studies
Meta analysis
Home COVID-19 treatment researchAcetaminophenAcetaminophen (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -18% Improvement Relative Risk Case -27% Acetaminophen  Chandan et al.  Prophylaxis Is prophylaxis with acetaminophen + combined treatments beneficial for COVID-19? PSM retrospective 17,190 patients in the United Kingdom (Jan - Jul 2020) Study compares with NSAIDs, results vs. placebo may differ Higher mortality (p=0.35) and more cases (p=0.17), not sig. Chandan et al., Arthritis & Rheuma.., Apr 2021 Favors acetaminophen Favors NSAIDs

Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID-19

Chandan et al., Arthritis & Rheumatology, doi:10.1002/art.41593
Apr 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 12,457 patients prescribed paracetamol with codeine/dihydrocodeine and 13,202 prescribed NSAIDs, showing no significant differences in cases and mortality. Patients prescribed codeine/dihydrocodeine may have different susceptibility to COVID-19. Paracetamol is also known as acetaminophen, Tylenol, Panadol, Calpol, Tempra, Calprofen, Doliprane, Efferalgan, Grippostad C, Dolo, Acamol, Fevadol, Crocin, and Perfalgan.
risk of death, 17.6% higher, HR 1.18, p = 0.35, treatment 71 of 8,595 (0.8%), control 79 of 8,595 (0.9%), adjusted per study, inverted to make HR<1 favor treatment, propensity score matching, multivariable.
risk of case, 26.6% higher, HR 1.27, p = 0.17, treatment 8,595, control 8,595, adjusted per study, inverted to make HR<1 favor treatment, propensity score matching, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Chandan et al., 29 Apr 2021, retrospective, United Kingdom, peer-reviewed, mean age 65.4, 24 authors, study period 30 January, 2020 - 31 July, 2020, this trial compares with another treatment - results may be better when compared to placebo, this trial uses multiple treatments in the treatment arm (combined with codeine or dihydrocodeine) - results of individual treatments may vary.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAcetaminophenAll
Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID‐19
Joht Singh Chandan, Dawit Tefra Zemedikun, PhD Rasiah Thayakaran, Nathan Byne, Samir Dhalla, Dionisio Acosta‐mena, MSc Krishna M Gokhale, Tom Thomas, MD Christopher Sainsbury, MSc Anuradhaa Subramanian, MBBCh Jennifer Cooper, Astha Anand, Kelvin O Okoth, Jingya Wang, Nicola J Adderley, Thomas Taverner, Alastair K Denniston, Janet Lord, G Neil Thomas, DPhil Christopher D Buckley, PhD Karim Raza, Neeraj Bhala, MD, IOEM Krishnarajah Nirantharakumar, Shamil Haroon
Arthritis & Rheumatology, doi:10.1002/art.41593
Objective. To identify whether active use of nonsteroidal antiinflammatory drugs (NSAIDs) increases susceptibility to developing suspected or confirmed coronavirus disease 2019 (COVID-19) compared to the use of other common analgesics. Methods. We performed a propensity score-matched cohort study with active comparators, using a large UK primary care data set. The cohort consisted of adult patients age ≥18 years with osteoarthritis (OA) who were followed up from January 30 to July 31, 2020. Patients prescribed an NSAID (excluding topical preparations) were compared to those prescribed either co-codamol (paracetamol and codeine) or co-dydramol (paracetamol and dihydrocodeine). A total of 13,202 patients prescribed NSAIDs were identified, compared to 12,457 patients prescribed the comparator drugs. The primary outcome measure was the documentation of suspected or confirmed COVID-19, and the secondary outcome measure was all-cause mortality. Results. During follow-up, the incidence rates of suspected/confirmed COVID-19 were 15.4 and 19.9 per 1,000 person-years in the NSAID-exposed group and comparator group, respectively. Adjusted hazard ratios for suspected or confirmed COVID-19 among the unmatched and propensity score-matched OA cohorts, using data from clinical consultations in primary care settings, were 0.82 (95% confidence interval [95% CI] 0.62-1.10) and 0.79 (95% CI 0.57-1.11), respectively, and adjusted hazard ratios for the risk of all-cause mortality were 0.97 (95% CI 0.75-1.27) and 0.85 (95% CI 0.61-1.20), respectively. There was no effect modification by age or sex. Conclusion. No increase in the risk of suspected or confirmed COVID-19 or mortality was observed among patients with OA in a primary care setting who were prescribed NSAIDs as compared to those who received comparator drugs. These results are reassuring and suggest that in the absence of acute illness, NSAIDs can be safely prescribed during the ongoing pandemic.
ADDITIONAL DISCLOSURES Authors Byne, Dhalla, and Acosta-Mena are employees of Cegedim Rx.
Baigent, Bhala, Emberson, Merhi, Abramson et al., Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials, Lancet
Basille, Thomsen, Madsen, Duhaut, Andrejak et al., Nonsteroidal antiinflammatory drug use and clinical outcomes of community-acquired pneumonia, Am J Respir Crit Care Med
Blak, Thompson, Dattani, Bourke, Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates, Inform Prim Care
Booth, What are the Read Codes?, Health Libr Rev
Bourgeois, Ferroni, Leruez-Ville, Varon, Thumerelle et al., Nonsteroidal anti-inflammatory drug without antibiotics for acute viral infection increases the empyema risk in children: a matched case-control study, J Pediatr
Collaborative, Elective surgery cancellations due to the COVID-19 pandemic: global predictive modelling to inform surgical recovery plans, Br J Surg
Davis, Lee, Kim, Advani, Peng et al., Use of non-steroidal anti-inflammatory drugs in US adults: changes over time and by demographic, Open Hear
Day, Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists, BMJ
Dubreuil, Louie-Gao, Peloquin, Choi, Zhang et al., Risk of myocardial infarction with use of selected non-steroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis, Ann Rheum Dis
Edelman, Gordon, Crothers, Akgün, Bryant et al., Association of prescribed opioids with increased risk of community-acquired pneumonia among patients with and without HIV, JAMA Intern Med
Fang, Karakiulakis, Roth, Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
Gokhale, Chandan, Toulis, Gkoutos, Tino et al., Data extraction for epidemiological research (DExtER): a novel tool for automated clinical epidemiology studies, Eur J Epidemiol
Haroon, Subramanian, Cooper, Anand, Gokhale et al., Renin-angiotensin system inhibitors and susceptibility to COVID-19 in patients with hypertension: a propensity score-matched cohort study in primary care, BMC Infect Dis
Health Organization, The use of non-steroidal antiinflammatory drugs (NSAIDs) in patients with COVID-19
Hoffmann, Kleine-Weber, Schroeder, Krüger, Herrler et al., SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell
Hopkins, COVID-19 Cashboard by the Center for Systems Science and Engineering
Jeong, Lee, Shin, Choe, Filion et al., Association between NSAIDs use and adverse clinical outcomes among adults hospitalised with COVID-19 in South Korea: a nationwide study, Clin Infect Dis
Little, Non-steroidal anti-inflammatory drugs and COVID-19 [editorial, BMJ
Lund, Kristensen, Reilev, Christensen, Thomsen et al., Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs tested positive for SARS-CoV-2: a Danish nationwide cohort study, PLoS Med
Maguire, Blak, Thompson, The importance of defining periods of complete mortality reporting for research using automated data from primary care, Pharmacoepidemiol Drug Saf
Nhs England, Acute use of non-steroidal anti-inflammatory drugs (NSAIDs) in people with or at risk of COVID-19
Qiao, Wang, Chen, Zhang, Liu et al., Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats, Cardiology
Sainsbury, Wang, Gokhale, Acosta-Mena, Dhalla et al., Sodium-glucose co-transporter-2 inhibitors and susceptibility to COVID-19: a population-based retrospective cohort study, Diabetes Obes Metab
Sungnak, Huang, Bécavin, Berg, Queen et al., SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes, Nat Med
Voiriot, Philippot, Elabbadi, Elbim, Chalumeau et al., Risks related to the use of non-steroidal anti-inflammatory drugs in community-acquired pneumonia in adult and pediatric patients
Wei, Neogi, Terkeltaub, Fenves, Zeng et al., Thiazide diuretics and risk of knee replacement surgery among patients with knee osteoarthritis: a general population-based cohort study, Osteoarthritis Cartilage
Wei, Wood, Dubreuil, Tomasson, Larochelle et al., Association of tramadol with risk of myocardial infarction among patients with osteoarthritis, Osteoarthritis Cartilage
Williamson, Walker, Bhaskaran, Bacon, Bates et al., Factors associated with COVID-19 death using OpenSAFELY, Nature
Zeng, Dubreuil, Larochelle, Lu, Wei et al., Association of tramadol with all-cause mortality among patients with osteoarthritis, JAMA
Zhou, Lou, Wang, Hu, Zhang et al., A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop